freeze-thaw cycle comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
In the diagram below, consider the amino-acids as single aliphatic monomers reacting with identical molecules to form a polyamide, focusing on solely the amine and acid groups. Ignore the substituent R groups – under the assumption the difference between the R groups are negligible:
== Bibliography == Dugo, Giovanni; Bonaccorsi, Ivana (2013). Citrus bergamia: Bergamot and its Derivatives. Medicinal and Aromatic Plants – Industrial Profiles (Book 51). CRC Press. ISBN 978-1439862278. Costa, Rosaria; Dugo, Paola; Navarra, Michele; Raymo, Vilfredo; Dugo, Giovanni; Mondello, Luigi (2010). "Study on the chemical composition variability of some processed bergamot (Citrus bergamia) essential oils". Flavour and Fragrance Journal. 25 (1): 4–12. doi:10.1002/ffj.1949. ISSN 0882-5734. Mangiola, Carlo; Postorino, Enrico; Gionfriddo, Francesco; Catalfamo, Maurizio; Manganaro, Renato; Calabrò, Giuseppe (October 2009). "Evaluation of the Genuineness of Cold-pressed Bergamot Oil". Perfumer & Flavorist: 26–31. Alp Kunkar and Ennio Kunkar, "Bergamotto e le sue essenze", Edizioni A Z A. Kunkar, C. Kunkar: Supercritical CO2 extraction of bergamot oil from peel; Int. Cong. Medicinal plants and essential oils- Anadolu üniversıtesi-Eskişehir Turkey
Thomas Bellchambers (born 9 July 1989) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). He is a current professional boxer. After playing for the Tasmanian Devils in the TAC Cup, he was drafted with pick 8 in the 2007 pre-season draft. He made his debut against Hawthorn in Round 11 of the 2008 AFL season. He announced his retirement from the AFL on the 15th of September 2020. Bellchambers, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. He announced his retirement on 15 September 2020, after 136 games. On 24/05/23 Bellchambers made his professional boxing debut Vs Cameron Mooney in Melbourne, Bellchambers won by KO in the 3rd round. The fight was in the heavyweight division. Bellchambers professional boxing record is 1-0. (1 by KO)
One of the main factors driving the Mexican drug war is widespread poverty. From 2004 to 2008, the portion of the population who received less than half of the median income rose from 17% to 21%, and the proportion of the population living in extreme or moderate poverty rose from 35% to 46% (52 million persons) between 2006 and 2010. Among the OECD countries, Mexico has the second-highest economic disparity between the extremely poor and the rich. The bottom ten percent in the income hierarchy has 1.36% of the country's resources, whereas the upper ten percent has almost 36%. The OECD also notes that Mexico's budgeted poverty alleviation and social development expenses are only about a third of the OECD average. In 2012, it was estimated that Mexican cartels employed over 450,000 people directly, and a further 3.2 million people's livelihoods depended on various parts of the drug trade. In cities such as Ciudad Juárez, up to 60% of the economy depended on illegal sources of income. As of 2023, an estimated 175,000 people are working for the cartels. The head of the U.S. Drug Enforcement Administration (DEA) reported that there are an estimated 45,000 members, associates, and brokers spread over more than 100 countries working under the Sinaloa cartel and the Jalisco New Generation cartel.
Sources: en.wikipedia.org
The 45-letter word pneumonoultramicroscopicsilicovolcanoconiosis is the longest English word that appears in a major dictionary. Originally coined to become a candidate for the longest word in English, the term eventually developed some independent use in medicine. It is referred to as "P45" by researchers. The 30-letter word pseudopseudohypoparathyroidism refers to an inherited disorder, named for its similarity to pseudohypoparathyroidism in presentation, which is in turn named for its similarity to hypoparathyroidism. This is the longest word that was not contrived with the sole intention of becoming the longest word. Floccinaucinihilipilification, at 29 letters and meaning the act of estimating something as being worth so little as to be practically valueless, or the habit of doing so, is the longest non-technical, coined word in Oxford Dictionaries of the English language. Antidisestablishmentarianism, at 28 letters, is the longest non-coined, non-systematic English word in Oxford Dictionaries. It refers to a 19th-century political movement that opposed the disestablishment of the Church of England as the state church of England.
Philip Zimbardo suggests we might also analyze happiness from a "time perspective". He suggested the sorting of people's focus in life by valence (positive or negative) and also by their time perspective (past, present, or future orientation). Doing so may reveal some individual conflicts, not over whether an activity is enjoyed, but whether one prefers to risk delaying gratification further. Zimbardo also believes research reveals an optimal balance of perspectives for a happy life; commenting, our focus on reliving positive aspects of our past should be high, followed by time spent believing in a positive future, and finally spending a moderate (but not excessive) amount of time in enjoyment of the present.
=== Properties === Cyanuric acid can be viewed as the cyclic trimer of the elusive chemical species cyanic acid, HOCN. The ring can readily interconvert between several structures via lactam–lactim tautomerism. Although the triol tautomer may have aromatic character, the keto form predominates in solution. The hydroxyl (-OH) groups assume phenolic character. Deprotonation with base affords a series of cyanurate salts:
Sources: en.wikipedia.org
== References == Velasco, Anna (July 15, 2007) "Renovation transforming look of county hospital." Birmingham News Bryant, Joseph (May 19, 2009) "Mayor Larry Langford: Birmingham should consider operating Cooper Green Mercy Hospital." Birmingham News
== Plot == Bree goes for a swim at the Ketea Aquatic Center and is joined in the Olympic-sized pool by her sister, Jonna, a recovering drug addict who is three months clean. When the pool manager, McGradey, catches the janitor, Clara, who is an ex-convict on parole, attempting to steal from the lost and found, he fires her and tells her to clean up. He then asks the customers to leave as the pool is closing for the holiday. While packing up, Bree notices her engagement ring is missing. Jonna sees the ring, stuck in the metal grille at the bottom of the pool and both dive in to retrieve it. McGradey, unaware the women are in the deep end, engages the fiberglass pool cover and leaves. Terrified, the siblings attempt to push the pool cover up or break through it, unsuccessfully. They find only one small hole. Jonna confesses she threw the ring into the pool because she is envious of Bree's successful lifestyle and recent engagement. Bree is angry at first, but then opens up about their abusive, alcoholic, drug-addicted father and the fire that led to his death. She reveals she is diabetic and requires insulin or she may fall into a diabetic coma. Clara, preparing to leave, sees the sisters. She steals Bree's cash, smartphone and credit card and says she will release them if Bree reveals her phone password and credit card PIN. Bree does so, but Clara turns the water heater off and leaves the sisters trapped for the whole night. Next morning, Clara returns to taunt them again.
PMID 26494468.{{cite journal}}: CS1 maint: multiple names: authors list (link) Gitashri Naiya, Stephanie Kaypee, Tapas Kundu, Siddhartha Roy (March 2015). "A Constrained Helical Peptide Against S100A4 Inhibits Cell Motility in Tumor Cells". Chemical Biology & Drug Design. 86 (4): 945–950. doi:10.1111/cbdd.12553. PMID 25763457. S2CID 30631236.{{cite journal}}: CS1 maint: multiple names: authors list (link) Tanjore Balganesh, Tapas Kundu, Tushar Kanti Chakraborty, Siddhartha Roy (July 2014). "Drug Discovery Research in India: Current State and Future Prospects". ACS Medicinal Chemistry Letters. 5 (7): 724–6. doi:10.1021/ml500183c. PMC 4094254. PMID 25050153.{{cite journal}}: CS1 maint: multiple names: authors list (link) Siddhartha Roy, Tapas Kundu (February 2014). "Gene regulatory networks and epigenetic modifications in cell differentiation". IUBMB Life. 66 (2): 100–109. doi:10.1002/iub.1249. PMID 24574067. S2CID 205968012. Siddhartha Roy, Piya Ghosh, Neeladri Roy, Abhishek Mazumder, Koushik Roy, Asit Kumar Manna, Shampa Mallick, Israr Ahmed (May 2012). "Peptide based Molecules as Protein-Protein Interaction Inhibitors: Tools for Chemical Genetics and Therapy". Current Chemical Biology. 6 (2): 145–163. doi:10.2174/2212796811206020145.{{cite journal}}: CS1 maint: multiple names: authors list (link) DNA-Bound p53-DNA-Binding Domain Interconverts between Multiple Conformations: Implications for Partner Protein Recognition.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.